Eko creates digital health solutions. Its solutions include artificial intelligence (AI) enabled stethoscopes, patient and provider software, and AI-powered analytics that enable doctors, nurses, researchers, and entire health systems to change care for the heart. It serves clients in the healthcare sector. It was founded in 2013 and is based in Oakland, California.
Eko's Product Videos
ESPs containing Eko
The ESP matrix leverages data and analyst insight to identify and rank leading companies in a given technology landscape.
The at-home electrocardiogram (ECG) monitoring market provides individuals with access to medical-grade heart monitoring technology from their own homes. Vendors offer products such as smart stethoscopes, wearable ECG monitors, and portable ECG devices to detect irregularities in heart rhythm and provide real-time data to clinicians. With the use of AI algorithms, patients and healthcare professio…
Eko's Products & Differentiators
3M™ Littmann® CORE Digital Stethoscope
The 3M™ Littmann® CORE Digital Stethoscope is the most advanced stethoscope on the market. With data-driven AI, the Littmann CORE combines outstanding acoustics, comfort, and quality with advanced digital innovations from Eko. Healthcare providers can listen with up to 40x sound amplification and active noise cancellation, which eliminates distracting background noise on the front lines. The Littmann CORE pairs with Eko software that provides FDA-cleared automated murmur detection. It’s the only stethoscope on the market to wirelessly stream heart sounds to a HIPAA-compliant app and the first to integrate heart sounds directly into the patient’s electronic health record.
Research containing Eko
Get data-driven expert analysis from the CB Insights Intelligence Unit.
CB Insights Intelligence Analysts have mentioned Eko in 13 CB Insights research briefs, most recently on Aug 9, 2023.
Expert Collections containing Eko
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Eko is included in 7 Expert Collections, including Artificial Intelligence.
Companies developing artificial intelligence solutions, including cross-industry applications, industry-specific products, and AI infrastructure solutions.
Value-Based Care & Population Health
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
The winners of the 4th annual CB Insights AI 100.
Digital Health 150
The winners of the second annual CB Insights Digital Health 150.
The digital health collection includes vendors developing software, platforms, sensor & robotic hardware, health data infrastructure, and tech-enabled services in healthcare. The list excludes pureplay pharma/biopharma, sequencing instruments, gene editing, and assistive tech.
Eko has filed 3 patents.
Cardiac arrhythmia, Sensors, Cardiology, Cardiac electrophysiology, Wireless networking
Cardiac arrhythmia, Sensors, Cardiology, Cardiac electrophysiology, Wireless networking
Latest Eko News
Nov 15, 2023
Real-world evidence from the AHA Scientific Sessions 2023 demonstrated that Eko's AI doubles valvular heart disease detection sensitivity over traditional methods Eko Health's AI-enabled technology marketed as SENSORA November 14, 2023 — Eko Health, Inc. , a leader in AI technology for heart and lung disease detection, today unveiled new clinical data at the 2023 American Heart Association Scientific Sessions. This data demonstrated the real-world clinical efficacy of Eko's AI-enabled S ENSORA™ Platform to quickly and accurately detect structural murmurs associated with valvular heart disease. Valvular heart disease (VHD) is a medical condition present in over 50% of adults over the age of 65. VHD can lead to heart failure, stroke, and death, and if left undetected and untreated, can progress from moderate to severe within one year . Unfortunately, symptoms of VHD are frequently nonspecific , and more than half of patients with moderate to severe disease are asymptomatic , making VHD challenging to detect with conventional medical practice. The study published in Circulation, " Real-World Evaluation of an Artificial Intelligence-Enabled Digital Stethoscope for Detecting Undiagnosed Valvular Heart Disease in Primary Care ," evaluated the performance of an Eko digital stethoscope paired with the company's FDA-cleared structural murmur detection algorithm (AI method) versus auscultation with an analog stethoscope in the primary care setting (standard method) in identifying previously undiagnosed VHD. The study found that the AI method showed over two times improvement in the detection sensitivity of VHD associated with a murmur. The AI method performed at 94.1% sensitivity and 84.5% specificity, compared to the standard method of 41.2% sensitivity and 95.5% specificity. Overall, the results indicate that the standard method under-detects across the board, leading to a lower sensitivity when disease is present and higher specificity when disease is not. Accordingly, the AI method identified 22 patients with moderate or greater VHD who were previously undiagnosed, while the standard method identified eight previously undiagnosed patients. These results suggest that using Eko's AI-enabled technology in primary care may significantly increase earlier VHD discovery, facilitate appropriate patient care, and improve outcomes. "The implications of undiagnosed or late diagnosis of valvular heart disease are dire, as well as costly to our health system," said Lead Author and Principal Investigator Moshe Rancier, M.D., Senior Medical Director of Mass General Brigham Community Physicians in Lawrence, Massachusetts. "This study demonstrates that patients can be more effectively evaluated for VHD in primary care by augmenting the standard cardiac exam with AI-enabled technology." "These results mark a significant step forward in utilizing AI-powered sensors for upstream cardiovascular disease detection," said Connor Landgraf, Co-founder & CEO of Eko Health. "With over 40 clinical validation and real-world studies initiated, we pride ourselves in developing clinically useful tools that assist clinicians with giving their patients the best care possible." The study's limitations include the sample size of the study group at 369 patients. However, enrollment is ongoing, and researchers plan to collect up to 12 months of patient follow-up data to evaluate clinical outcomes. Eko's AI-enabled technology is commercially available in the U.S. and marketed to health systems as the SENSORA Platform. For more information: ekosensora.com
Eko Frequently Asked Questions (FAQ)
When was Eko founded?
Eko was founded in 2013.
Where is Eko's headquarters?
Eko's headquarters is located at 1212 Broadway, Oakland.
What is Eko's latest funding round?
Eko's latest funding round is Grant - II.
How much did Eko raise?
Eko raised a total of $127.4M.
Who are the investors of Eko?
Investors of Eko include National Institutes of Health, MedTech Innovator, Artis Ventures, NTT Venture Capital, DigiTx Partners and 17 more.
Who are Eko's competitors?
Competitors of Eko include Happitech, TytoCare, Sonavi Labs, AliveCor, Strados Labs and 7 more.
What products does Eko offer?
Eko's products include 3M™ Littmann® CORE Digital Stethoscope and 4 more.
Compare Eko to Competitors
StethoMe focuses on the development of artificial intelligence in the fields of healthcare and telemedicine. It detects abnormal sounds in the respiratory system. Its core product is an electronic stethoscope that coordinates with a smartphone application and specially designed algorithms. The company was founded in 2015 and is based in Poznan, Poland.
Aevice Health offers a respiratory monitoring device. It monitors a child's asthma condition. Its solutions include the AeviceMD Monitoring System, which provides a comprehensive patient management platform for chronic respiratory disease management. Aevice Health was founded in 2016 and is based in Singapore.
AliveCor focuses on the creation of machine learning techniques to enable proactive heart care. It offers artificial intelligence (AI) enabled, machine learning (ML) powered electrocardiogram (ECG) sensors that deliver heart data at any time. The company's digital tools help patients access, manage and share their data, and connect with cardiologists to understand and manage their heart health. It was formerly known as AliveUSA. AliveCor was founded in 2011 and is based in Mountain View, California.
Healthy.io develops a healthcare technology company. The company offers services such as home urinalysis and digital wound care, enabling patients to conduct tests and manage their health at their convenience using their smartphones. It primarily serves the healthcare industry, providing solutions that help healthcare providers and systems improve patient interactions and access to care. It was founded in 2013 and is based in Tel Aviv, Israel.
Happitech develops a heart rhythm software development kit for Android and iPhone operating systems. The company offers algorithms allowing medical-grade vital signs monitoring directly through a smartphone. The company was founded in 2015 and is based in Rotterdam, Netherlands.
Heart Care is a health care company focused on the domain of heart health monitoring. The company offers a service that allows users to track their heart rate in real time, providing insights into how their health responds to daily activities, and promoting a healthier and more controlled routine. Heart Care primarily serves individuals seeking to monitor their heart health and maintain a healthy lifestyle. It was founded in 2017 and is based in Sao Paulo, Brazil.